AXA Mansard launches iMED cancer plan
Analysis based on 6 articles · First reported Aug 19, 2026 · Last updated Sep 08, 2026
The launch of iMED could strengthen AXA — AXA Mansard Health's competitive position in Nigeria's health insurance market by addressing the growing demand for cancer and specialized care coverage. This may positively impact the company's customer base and revenue, though the overall market impact is limited given the niche nature of the product.
AXA — AXA Mansard Health, a Nigerian health insurance provider, has introduced iMED, an international healthcare plan offering Nigerians coverage for cancer and other complex conditions, including organ and bone marrow transplants, chemotherapy, radiotherapy, and international emergency medical assistance. The plan provides access to accredited healthcare providers in Nigeria, the United States, the United Kingdom, and United Arab Emirates — Dubai. The launch responds to the high cancer burden in Nigeria, where over 150,000 new cases and 90,000 deaths occur annually, according to the Global Cancer Observatory. CEO Bashir Adewale Adeniyi emphasized the company's commitment to reducing barriers to specialized treatment and bringing world-class healthcare closer to Nigerians.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard